Helium

Summary

Helium (CHEMBL1796997) is an approved small molecule (ATC V03AN03); indicated across 2 conditions including chronic obstructive pulmonary disease and status asthmaticus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AN03
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 4.0026 Da · He

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1796997
Name	Helium
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	23987
ChEBI	CHEBI:30217
ATC	V03AN03
Molecular formula	He
Molecular weight	4.0026
InChIKey	SWQJXJOGLNCZEY-UHFFFAOYSA-N

SMILES: [He]

IUPAC name: helium

Also known as: E-939, E939, Helium, Helium-4, INS NO.939, INS-939, HELIUM

Patent coverage: 287,071 distinct patent families (690,625 SureChEMBL compound mentions), from 14 matched compound structure(s). One matched structure accounts for 690,595 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
status asthmaticus	2	MONDO:0004766	EFO:0008590

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01155310	PHASE3	TERMINATED	Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
NCT00315965	PHASE1	UNKNOWN	Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects
NCT00394225	Not specified	COMPLETED	Helium-Hyperoxia and 6MWT Distance in COPD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).